Sugi Predict

Sugi Predict / Targets / CHIA

CHIA

Acidic mammalian chitinase · Q9BZP6 · CHIA on Sugi Atlas →

9,189 patent compounds predicted against CHIA, 6,209 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1968987 SCHEMBL1968987 0.54 8/20
SCHEMBL2455907 SCHEMBL2455907 0.46 8/20
SCHEMBL5212497 SCHEMBL5212497 0.44 8/20
SCHEMBL1967611 SCHEMBL1967611 0.54 7/20
SCHEMBL1242233 SCHEMBL1242233 0.55 6/20
SCHEMBL652789 SCHEMBL652789 0.34 5/20
SCHEMBL652790 SCHEMBL652790 0.34 5/20
SCHEMBL1969047 SCHEMBL1969047 0.46 3/20
SCHEMBL3154343 SCHEMBL3154343 0.48 2/20
SCHEMBL1994355 SCHEMBL1994355 0.45 2/20
SCHEMBL4649492 SCHEMBL4649492 0.43 2/20
SCHEMBL586739 SCHEMBL586739 0.43 2/20
SCHEMBL937025 SCHEMBL937025 0.42 2/20
SCHEMBL520505 SCHEMBL520505 0.39 2/20
SCHEMBL2116076 SCHEMBL2116076 0.39 2/20
SCHEMBL5359873 SCHEMBL5359873 0.39 2/20
SCHEMBL586955 SCHEMBL586955 0.36 2/20
SCHEMBL586956 SCHEMBL586956 0.36 2/20
SCHEMBL586957 SCHEMBL586957 0.36 2/20
SCHEMBL5469941 SCHEMBL5469941 0.35 2/20

Clinical trials — most relevant to CHIA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers PHASE1COMPLETED
IVAC MUTANOME Phase I Clinical Trial PHASE1COMPLETED
The Connection Between Liver Disease and Chitinase Proteins nanUNKNOWN
The Role of Peripheral and Tissue Chitinase 3-like 1 Protein Levels as a Bio-marker in IBD nanCOMPLETED
Exploration of Immunity in Gaucher Disease nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
The Genetics of Chiari Type I Malformation nanCOMPLETED
Genetic Analysis of the Chiari I Malformation nanCOMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma nanCOMPLETED
Chitinases and Transforming Growth Factor Beta (TGFB) in Human Asthma nanCOMPLETED
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection nanCOMPLETED
Evaluation of Different Serum Cartilage Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Subjects nanAVAILABLE
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Transcriptional and Immune Parameters of Response to Belimumab nanCOMPLETED
Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold nanCOMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance nanUNKNOWN
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease nanUNKNOWN
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease nanUNKNOWN
Study of the Sex Differences in Inflammatory Diseases in Children nanUNKNOWN
Biomarker for Gaucher Disease: BioGaucher (BioGaucher) nanWITHDRAWN
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection nanUNKNOWN
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis nanRECRUITING
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients nanCOMPLETED
CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment nanCOMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CHIA binder may also engage these)

ProteinNameSimilarity
Q6RY07 — 1.000 Q6RY07 →
Q91XA9 — 0.999 Q91XA9 →
Q95M17 — 0.993 Q95M17 →
CHIT1 Chitotriosidase-1 0.979 landscape →
E9QRF2 — 0.974 E9QRF2 →
P32470 — 0.974 P32470 →
E9ERT9 — 0.970 E9ERT9 →
Q873X9 — 0.969 Q873X9 →
O14456 — 0.969 O14456 →
O35744 — 0.967 O35744 →
Q11174 — 0.967 Q11174 →
P48827 — 0.966 P48827 →
Q91Z98 — 0.966 Q91Z98 →
A6N6J0 — 0.966 A6N6J0 →
Q1E3R8 — 0.965 Q1E3R8 →
C5P230 — 0.965 C5P230 →
Q9WTV1 — 0.964 Q9WTV1 →
Q61362 — 0.964 Q61362 →
CHI3L1 Chitinase-3-like protein 1 0.964 landscape →
Q9D7Q1 — 0.964 Q9D7Q1 →
P0CB51 — 0.964 P0CB51 →
Q7YS85 — 0.964 Q7YS85 →
Q5RBP6 — 0.964 Q5RBP6 →
CHI3L2 Chitinase-3-like protein 2 0.963 landscape →
Q29411 — 0.962 Q29411 →
G5EAZ3 — 0.960 G5EAZ3 →
P30922 — 0.960 P30922 →
A0A2U7QU15 — 0.958 A0A2U7QU15 →
Q9HEZ1 — 0.958 Q9HEZ1 →
Q92222 — 0.958 Q92222 →